Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release the drug, and studied its...

Descripción completa

Detalles Bibliográficos
Autores principales: Marslin, Gregory, Revina, Ann Mary, Khandelwal, Vinoth Kumar Megraj, Balakumar, Krishnamoorthy, Prakash, Jose, Franklin, Gregory, Sheeba, Caroline J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425327/
https://www.ncbi.nlm.nih.gov/pubmed/25995626
http://dx.doi.org/10.2147/IJN.S75962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425327/
https://www.ncbi.nlm.nih.gov/pubmed/25995626
http://dx.doi.org/10.2147/IJN.S75962

Ejemplares similares